PRLD · Prelude Therapeutics Inc · Executive Compensation

$4.59 -0.08 (-1.71%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$366.30M

79.80M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Krishna Vaddi	Chief Executive Officer	$615,441	—	—	$412,744	$309,465	$10,350	$1,348,000
Bryant D. Lim	Chief Legal Officer, Corporate Secretary, and Chief Financial Officer	$477,500	—	—	$166,347	$193,200	$10,350	$847,397
Peggy Scherle	Ph. D. Chief Scientific Officer	$473,416	—	—	$145,523	$190,440	$10,350	$819,729

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Krishna Vaddi	Chief Executive Officer	$594,167	—	—	$1,446,379	$276,575	$10,350	$2,327,471
Jane Huang	President and Chief Medical Officer	$568,333	—	—	$595,671	$264,550	$10,350	$1,438,904
Bryant D. Lim	Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer	$444,167	—	—	$581,895	$166,500	$10,350	$1,202,912

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Krishna Vaddi	Chief Executive Officer	$572,667	—	—	$1,735,873	$330,625	$2,624	$2,641,789
Jane Huang	President and Chief Medical Officer	$545,833	—	—	$789,033	$316,250	$3,546	$1,654,662
Bryant D. Lim	Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer	$359,282	—	—	$1,086,904	$159,083	$9,497	$1,614,766

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Krishna Vaddi	Chief Executive Officer	$558,333	—	—	$2,498,244	$238,425	$9,150	$3,304,152
Jane Huang	President and Chief Medical Officer	$391,761	$4,450	$729,000	$1,627,660	$167,344	—	$2,920,215
Peggy Scherle	Chief Scientific Officer	$416,667	$300,000	—	$761,865	$142,800	$9,150	$1,630,482

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Krishna Vaddi	Chief Executive Officer	$544,192	—	—	$6,224,234	$265,688	$8,700	$7,042,814
Brian Piper	M.B.A Former Chief Financial Officer	$389,458	—	—	$2,518,565	—	—	$2,908,023
Peggy Scherle	Chief Scientific Officer	$408,271	—	—	$2,068,828	$156,000	$8,700	$2,641,799
Andrew P. Combs	EVP and Head of Chemistry	$406,461	—	—	$2,068,828	$156,000	—	$2,631,289
Jane Huang	President and Chief Medical Officer	—	—	—	—	—	—	—

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Krishna Vaddi	Ph.D.^(^^3)^ Chief Executive Officer	$417,058	—	$1,409,998	$9,576,741	$228,667	—	$11,632,464
Christopher Pierce	M.B.A. Executive Vice President andChief of Business Operations	$204,029	—	—	$3,594,492	$132,344	—	$3,930,865
Deborah Morosini	Executive Vice President andChief of Clinical Affairs	$194,466	—	—	$3,594,492	$132,344	—	$3,921,302
Peggy Scherle	Chief Scientific Officer	$347,865	—	—	$2,170,824	$171,552	—	$2,690,241
Andrew P. Combs	EVP and Head of Chemistry	$321,538	—	—	$1,533,537	$160,988	—	$2,016,063
Brian Piper	M.B.A Former Chief Financial Officer	$328,942	—	—	$1,471,410	$160,988	—	$1,961,340

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Krishna Vaddi	Chief Executive Officer	$315,000	—	$815,000	$828,125	$121,275	—	$2,079,400

Executive changes

Person	Role	Change	Effective	Filed
Charles Q. Morris, M.D.	Chief Medical Officer	Appointed	2026-04-20	2026-04-15
Jane Huang, M.D.	President and Chief Medical Officer	Resigned	2025-11-03	2025-11-04
Katina Dorton	Class III director	Appointed	2025-10-17	2025-10-17
Mardi Dier	Class III member of the Board of Directors	Resigned	2025-10-17	2025-10-17
Paul Scherer, M.D.	Class III director	Appointed	2025-06-12	2025-06-13
Bryant D. Lim	permanent Chief Financial Officer	Appointed	2025-02-03	2025-02-05

Key facts CIK 1678660 CUSIP 74065P101 13F (30d) 49 filings 49 filers Visit website Investor relations